|
Post by hellodolly on Feb 28, 2024 19:05:03 GMT -5
Feb 28, 2024 11:33 EST Price Target Maintained With a $6.50/Share by Cantor Fitzgerald
|
|
|
Post by mytakeonit on Feb 28, 2024 20:36:40 GMT -5
I think he meant $6.50 for this week Friday.
But, that's almosteveryone'stakeonit
|
|
|
Post by sla55 on Feb 29, 2024 10:40:16 GMT -5
markets.businessinsider.com/news/stocks/mannkind-corporation-strong-growth-and-clinical-advancements-prompt-buy-rating-1033114200#:~:text=MannKind%27s%20total%20revenues%20have%20shown,pronounced%20increase%20in%20royalty%20revenues. MannKind Corporation: Strong Growth and Clinical Advancements Prompt Buy Rating Feb. 28, 2024, 07:55 AM MannKind (MNKD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andreas Argyrides from Wedbush reiterated a Buy rating on the stock and has a $10.00 price target. Andreas Argyrides has given his Buy rating due to a combination of factors including strong financial performance and promising clinical advancements. MannKind’s total revenues have shown significant growth both quarterly and year-over-year, exceeding Wedbush’s estimates. The growth is largely driven by the success of Tyvaso DPI, a product they manufacture in collaboration with United Therapeutics, which has seen a pronounced increase in royalty revenues. Additionally, Afrezza, MannKind’s inhaled insulin product, has also reported sales growth and is expected to see expanded market opportunities and increased prescriber adoption, further bolstered by the upcoming $35 insulin copay cap for Medicare and commercial insurance in 2024. Moreover, the company’s pipeline includes MNKD-101 for NTM lung disease and MNKD-201 for IPF, which are advancing into clinical trials in 2024. Argyrides notes the potential strategic benefits arising from a competitor’s paused enrollment in their trial, which could favorably impact MannKind’s MNKD-101 program. With sufficient cash reserves to fund operations for the foreseeable future and the anticipation of revealing data from the INHALE-3 trial for Afrezza in Type 1 Diabetes Mellitus at an upcoming conference, the company is well-positioned for future growth. These elements contribute to the analyst’s positive outlook and reiteration of an Outperform rating with a $10 twelve-month price target. Argyrides covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Ascendis Pharma, and RegenXBio. According to TipRanks, Argyrides has an average return of 12.2% and a 50.00% success rate on recommended stocks. In another report released yesterday, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $6.50 price target.
|
|
|
Post by ktim on Mar 1, 2024 12:56:54 GMT -5
Were any of these actually raises in estimates? Even with a lot of "risk on" "FOMO" action in the overall market, this is a huge move in MNKD over the last few day. Doesn't seem like EC alone should have moved the needle this much. Hopefully our trading range has been reset higher.
|
|
|
Post by peppy on Mar 1, 2024 13:08:12 GMT -5
Were any of these actually raises in estimates? Even with a lot of "risk on" "FOMO" action in the overall market, this is a huge move in MNKD over the last few day. Doesn't seem like EC alone should have moved the needle this much. Hopefully our trading range has been reset higher. MNKD share price is going to be taken over 5 dollars. MNKD revenue doubled, with another double in the cards for revenue. and they are getting rid of debt. 3 and 1/2 years of share price meandering chop and now, in these moments share price is being taken up. Binder, on the balance sheet.
|
|
|
Post by biffn on Mar 1, 2024 13:29:43 GMT -5
at what point do we start seeing shorts getting squeezed?
|
|
|
Post by wyattdog on Mar 1, 2024 13:34:21 GMT -5
if you listened to Martine Rothblatt's opening statement on the earnings call she said "To put it simply, MannKind sold a-tenth of their 10% royalty payment stream from us, which equates to 1% of Tyvaso DPI sales and they sold it to Sagard Healthcare Partners for $150 million, plus other milestones. That implies an external valuation of the entirety of the Tyvaso DPI revenue stream of $15 billion before even factoring in the additional potential milestones. That's well above the current market cap for our entire business. And importantly, this transaction valuation is far above The Wall Street valuation of our entire company as a whole, and is for only one of our many products." I think people are finally catching on.
|
|
|
Post by ktim on Mar 1, 2024 13:50:36 GMT -5
Were any of these actually raises in estimates? Even with a lot of "risk on" "FOMO" action in the overall market, this is a huge move in MNKD over the last few day. Doesn't seem like EC alone should have moved the needle this much. Hopefully our trading range has been reset higher. MNKD share price is going to be taken over 5 dollars. MNKD revenue doubled, with another double in the cards for revenue.and they are getting rid of debt. 3 and 1/2 years of share price meandering chop and now, in these moments share price is being taken up. Binder, on the balance sheet. What do you mean by that line? Not another double for 2024. If you look at the "non risk adjusted" revenue estimates presented earlier by MNKD, it seems they are only expecting around 25-30% growth in revenue this year (appears the collaborations and services will drop, offsetting some of the royalties gain) . Yes, the same chart shows way more than doubling in the long term, but of course when you start getting into revenue projections based on binary FDA events, the revenue gets heavily discounted. Don't get me wrong, I think MNKD is undervalued even with reasonable risk discounting for pipeline. The royalty sale would tend to indicate Tyvaso alone would account for ~$5/share. I'm just delightedly surprised with the strong after EC appreciation given nothing new was really presented. The earnings, revenue and balance sheet info was what we knew going into the EC. Maybe people just liked Mike's tone of voice this time, lol Maybe as the quarters roll by without any bumps the WS "MNKD distrust" discounting will be dissipating.
|
|
|
Post by jkendra on Mar 1, 2024 14:07:00 GMT -5
So 30% growth would mean ~$60M more for 2024. That means $260M total for the year which would put us at $65M+ average revenues per quarter at the very least ? Again, chump change move so far since Q4 earnings call. Market cap seems extremely undervalued. What are Liquidia's total revenues again ?
|
|
|
Post by peppy on Mar 1, 2024 14:21:43 GMT -5
So 30% growth would mean ~$60M more for 2024. That means $260M total for the year which would put us at $65M+ average revenues per quarter at the very least ? Again, chump change move so far since Q4 earnings call. Market cap seems extremely undervalued. What are Liquidia's total revenues again ? Revenue was $3.7 million for the three months ended September 30, 2023, compared to $3.2 million for the three months ended September 30, 2022. liquidia.com/news-releases/news-release-details/liquidia-corporation-reports-third-quarter-2023-financial Net loss and comprehensive loss $ (15,790 ) $ (9,092 ) Net loss per common share, basic and diluted $ (0.24 ) $ (0.14 ) Weighted average common shares outstanding, basic and diluted 64,857,508 64,458,741
|
|
|
Post by alethea on Mar 1, 2024 14:56:23 GMT -5
So 30% growth would mean ~$60M more for 2024. That means $260M total for the year which would put us at $65M+ average revenues per quarter at the very least ? Again, chump change move so far since Q4 earnings call. Market cap seems extremely undervalued. What are Liquidia's total revenues again ? Liquidia's financial position is similar to MNKD's of 7 or 8 years ago AFTER being cut loose by Sanofi. Liquidia has been pumped way up to its current price. It's going to be abused and shorted into the ground going forward.... just like has been done to MNKD for years now.
|
|
|
Post by ktim on Mar 1, 2024 15:07:09 GMT -5
So 30% growth would mean ~$60M more for 2024. That means $260M total for the year which would put us at $65M+ average revenues per quarter at the very least ? Again, chump change move so far since Q4 earnings call. Market cap seems extremely undervalued. What are Liquidia's total revenues again ? You don't own enough shares if your MNKD gains since earnings have been chump change, lol MNKD has been my biggest market gains since then, even accounting for things like NVDA and AVGO being on a tear.
|
|
|
Post by jkendra on Mar 1, 2024 15:15:35 GMT -5
So 30% growth would mean ~$60M more for 2024. That means $260M total for the year which would put us at $65M+ average revenues per quarter at the very least ? Again, chump change move so far since Q4 earnings call. Market cap seems extremely undervalued. What are Liquidia's total revenues again ? You don't own enough shares if your MNKD gains since earnings have been chump change, lol MNKD has been my biggest market gains since then, even accounting for things like NVDA and AVGO being on a tear. ? ? ? Chump change move relative to MNKD's fair market value.
|
|
|
Post by sportsrancho on Mar 1, 2024 16:41:39 GMT -5
|
|
|
Post by sayhey24 on Mar 1, 2024 22:00:51 GMT -5
Great video - I lived a time like that. For MNKD at least we had the safety net of Martine. The original MNKD "cult" would have figured out something but I am sure Mike was having more than a few sleepless nights back in the summer of 2018.
|
|